Clearside Q3 net loss $9.3M; inks BioCryst licensing deal for DME with $5M upfront

Clearside Biomedical, Inc.

2023-Q3 EPS reported -$0.45 revenue$1,881,000

Net loss of $9.3M ($0.15/share) vs $7.8M loss ($0.13/share) in Q3 2022.
Cash $28.8M at Sep 30; +$5M upfront from BioCryst extends runway into Q4 2024.
Licensed avoralstat (plasma kallikrein inhibitor) to BioCryst for DME; up to $77.5M milestones plus royalties.
Completed recruitment in Phase 2b ODYSSEY wet AMD trial; topline data expected Q3 2024.
Arctic Vision finished Phase 3 UME trial enrollment in China; Bausch+Lomb granted new CPT code for XIPERE.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Clearside Biomedical, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, Clearside Biomedical, Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter ended September 30, 2023, as well as information regarding a conference call to discuss these financial results and the Registrant’s recent corporate highlights.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062941

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.